RPTH Recap: Thromboprophylaxis w/ rivaroxaban in patients w/ malignancy & central venous lines

RPTH Recap: Thromboprophylaxis w/ rivaroxaban in patients w/ malignancy & central venous linesПодробнее

Venous Thromboembolism: Assessing the Risk in Hospital...and Beyond [MUST WATCH]Подробнее

Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI resultsПодробнее

Rivaroxaban for thromboprophylaxis in high risk ambulatory patients with cancerПодробнее

CASSINI: can we prevent thrombosis in cancer patients who are at risk?Подробнее

RPTH Research Recap: Epidemiology of CVST and CVST with thrombocytopeniaПодробнее

RPTH Research Recap | Risk of VTE in Patients with COVID-19: A Systematic Review and Meta-analysisПодробнее

Alok A. Khorana: Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer PatientsПодробнее

RPTH Research Recap | Rivaroxaban in Acute Venous Thromboembolism: UK Prescribing ExperienceПодробнее

RPTH Research Recap | The Psychological Impact of Pulmonary EmbolismПодробнее

Updated ASCO guidelines for VTE in cancerПодробнее

SECRET trial: rivaroxaban for cerebral venous thrombosisПодробнее

Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic DiseaseПодробнее

Extended VTE Prophylaxis workshop with Dr P Gross & Dr R IkesakaПодробнее

Thromboprophylaxis | Perioperative ConsiderationПодробнее

RPTH Research Recap: VTE secondary to hospitalization for COVID-19: long-term patient managementПодробнее

Quality assessment looking at rivaroxaban for cancer-related thrombosisПодробнее

Medical Grand Rounds, October 21, 2021Подробнее

Rivaroxaban beats aspirin for VTEПодробнее